Eli Lilly will acquire Morphic, a Massachusetts-based biopharmaceutical company, for about $3.2 billion by the end of 2024.
Morphic's lead product is an oral small molecule inhibitor that is a potential inflammatory bowel disease treatment, according to a July 8 news release from Eli Lilly. The biopharmaceutical business is also testing therapies for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
Both company's boards have approved the transaction, which is expected to finalize in the third quarter of 2024.